Macsita-M 50/1000 Tablet is a combination oral antihyperglycemic agent containing Sitagliptin 50 mg and Metformin 1000 mg, indicated for the management of type 2 diabetes mellitus. Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that enhances the incretin system, thereby increasing insulin release and decreasing glucagon levels in a glucose-dependent manner. Metformin, a biguanide, improves insulin sensitivity, reduces hepatic glucose production, and enhances peripheral glucose uptake. The synergistic action of these two agents helps achieve better glycemic control in patients inadequately controlled on diet and exercise alone or on monotherapy. Macsita-M 50/1000 is typically prescribed as part of a comprehensive diabetes management plan including diet, exercise, and regular blood glucose monitoring. It is contraindicated in patients with renal impairment, metabolic acidosis, or hypersensitivity to its components. Common adverse effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, which often subside with continued use. Regular monitoring of renal function and blood glucose levels is recommended during therapy. This combination tablet offers a convenient dosing option to improve adherence and optimize glycemic control in type 2 diabetes patients.